Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

Aliment Pharmacol Ther 31, 1296–1309

[1]  P. Atanasov,et al.  Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn’s Disease , 2012, PharmacoEconomics.

[2]  S. Schreiber.  Certolizumab pegol for the treatment of Crohn’s disease , 2011, Therapeutic advances in gastroenterology.

[3]  S. Fine.  Adalimumab for the treatment of fistulas in patients with Crohn's disease. , 2011, Inflammatory bowel diseases.

[4]  J. Chao,et al.  Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease , 2009, European journal of gastroenterology & hepatology.

[5]  Philippe Marteau,et al.  Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease , 2009, Inflammatory bowel diseases.

[6]  W. Sandborn,et al.  Adalimumab safety in global clinical trials of patients with Crohn's disease , 2009, Inflammatory bowel diseases.

[7]  K. Bodger,et al.  Cost‐effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient‐level cost data , 2009, Alimentary pharmacology & therapeutics.

[8]  M. Vos,et al.  961 Infliximab Discontinuation in Crohn's Disease Patients in Stable Remission On Combined Therapy with Immunosuppressors: A Prospective Ongoing Cohort Study , 2009 .

[9]  J. Chao,et al.  S1040 Dosage Pattern of Adalimumab in Real-World Clinical Practice and Predictors of Dosage Increase in Patients with Crohn's Disease in the US , 2009 .

[10]  P. Rutgeerts,et al.  751f One Year Data from the Sonic Study: A Randomized, Double-Blind Trial Comparing Infliximab and Infliximab Plus Azathioprine to Azathioprine in Patients with Crohn's Disease Naive to Immunomodulators and Biologic Therapy , 2009 .

[11]  P. Rutgeerts,et al.  Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial , 2009, The American Journal of Gastroenterology.

[12]  J. Chao,et al.  10 - Patterns and predictors of dosage increase in patients treated with adalimumab for Crohn's disease in the United States , 2009 .

[13]  B. Dijkmans,et al.  Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases , 2009, Annals of the rheumatic diseases.

[14]  S. Hanauer,et al.  Management of Crohn's Disease in Adults , 2001, The American Journal of Gastroenterology.

[15]  D. Rubin,et al.  Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients With Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial , 2008, The American Journal of Gastroenterology.

[16]  P. Rutgeerts,et al.  Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. , 2008, Gastroenterology.

[17]  K. Van Steen,et al.  Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort , 2008, Gut.

[18]  P. Rutgeerts,et al.  P087 - SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy , 2008 .

[19]  E. Wu,et al.  Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[20]  P. Rutgeerts,et al.  Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. , 2008, Gastroenterology.

[21]  P. Rutgeerts,et al.  M1143 Benefits of Dosage Adjustment with Adalimumab in Crohn's Disease: An Analysis of the CHARM Trial , 2008 .

[22]  J. Schweizer,et al.  Infliximab dependency in pediatric Crohn's disease: Long‐term follow‐up of an unselected cohort , 2008, Inflammatory bowel diseases.

[23]  M. Vos,et al.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial , 2008, The Lancet.

[24]  J. Chao,et al.  The costs of Crohn's disease in the United States and other Western countries: a systematic review , 2008, Current medical research and opinion.

[25]  S. Rudolph,et al.  Long-Term Durability of Crohn’s Disease Treatment with Infliximab , 2008, Digestive Diseases and Sciences.

[26]  F. Casellas,et al.  Sustained improvement of health‐related quality of life in Crohn's disease patients treated with infliximab and azathioprine for 4 years , 2007, Inflammatory bowel diseases.

[27]  M. Regueiro,et al.  Infliximab dose intensification in Crohn's disease , 2007, Inflammatory bowel diseases.

[28]  S. Hanauer,et al.  Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial , 2007, Gut.

[29]  S. Schreiber,et al.  Maintenance therapy with certolizumab pegol for Crohn's disease. , 2007, The New England journal of medicine.

[30]  P. Rutgeerts,et al.  American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. , 2007, Gastroenterology.

[31]  S. Hanauer,et al.  Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab , 2007, Annals of Internal Medicine.

[32]  S. Schreiber,et al.  P178 Early Crohn's Disease Shows High Levels of Remission to Therapy with Adalimumab: Sub-Analysis of Charm , 2007 .

[33]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[34]  J. Sabate,et al.  Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-up. , 2006, Gastroenterologie clinique et biologique.

[35]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[36]  M. Bala,et al.  Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. , 2005, Gastroenterology.

[37]  M. Bala,et al.  Remission in Patients with Crohn's Disease is Associated with Improvement in Employment and Quality of Life and a Decrease in Hospitalizations and Surgeries , 2004, American Journal of Gastroenterology.

[38]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[39]  J. Belaiche,et al.  Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease , 2001, Gut.

[40]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[41]  J. Rochon,et al.  Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. , 1994, Gastroenterology.